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Abstract 
Tumor microenvironments present significant barriers to penetration by antibodies and 
immunoconjugates and are difficult to study in vitro. Cells cultured as monolayers typically 
exhibit less resistance to therapy than those grown in vivo. Therefore, it is important to de-
velop an alternative research model that better represents in vivo tumors. We have developed 
a protocol to produce multicellular spheroids, a simple and more relevant model of in vivo 
tumors that allows for further investigations of the microenvironmental effects on drug 
penetration and tumor cell killing. The protocol is used to produce in vitro three-dimensional 
tumor spheroids from established human cancer cell lines and primary cancer cells isolated 
from patients without the use of any extracellular components. To study the ability of tu-
mor-targeting immunoconjugates to penetrate these tumor spheroids in vitro, we have used an 
immunotoxin targeting mesothelin, a surface protein expressed in malignant mesotheliomas. 
This method for producing consistent, reproducible 3D spheroids may allow for improved 
testing of novel monoclonal antibodies and other agents for their ability to penetrate solid 
tumors for cancer therapy. 
Key words: multicellular spheroids, protocol, monoclonal antibody therapy 
INTRODUCTION 
Treatment of solid tumors remains a major chal-
lenge despite the availability of a vast number of an-
ti-cancer agents. Antibody-based therapies represent 
a promising new approach for treating solid tumors. 
However, a major challenge involves delivering suf-
ficient amounts of antibodies and immunoconjugates 
within tumor masses. For an anti-cancer antibody 
agent to be successful, it must (a) be effective in the 
tumor microenvironment, and (b) reach the tumor 
cells in optimal quantities to exert a therapeutic ef-
fect5. Tumors are more resistant to therapy than can-
cer cells cultured as monolayers. This can be ex-
plained by “multicellular resistance,” a mechanism 
for drug resistance attributed to cell-cell contacts, 
cell-matrix contacts, and the three-dimensional (3D) 
shape found in tissue5. The majority of the ~1013 cells 
in the human body are only within a few cell diame-
ters of a blood vessel. This feature facilitates the de-
livery of oxygen and nutrients to the cells that form 
the tissues of the body (Fig. 1)5 and also enables the 
efficient delivery of most medicines.   
Ivyspring  
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Figure 1. Schematic overview of the in vivo tumor and the in vitro tumor spheroid. Comparison of the com-
ponents between a tumor and spheroid model. 
 
In light of this, the solid tumor microenviron-
ment has several major characteristics, including hy-
poxia, large distances between blood vessels, high 
interstitial fluid pressure, structure and composition 
of the extracellular matrix, and cell–cell adhesion. 
Overall, these features of the tumor microenviron-
ment limit the delivery of anticancer drugs to cancer 
cells that are situated far from blood vessels. Multi-
cellular resistance acquired by tumor cells may con-
tribute to difficulties in translating promising findings 
from in vitro studies into clinical therapy. In vitro 
multicellular cancer spheroids have begun to bridge 
the complexity gap between monolayer cell culture 
and in vivo tumors and have become valuable models 
in the study of drug resistance. Spheroids exhibit 
many features of the tumor microenvironment and 
model the avascular region of tumors that is de-
pendent on diffusion (Fig. 1)4. A simple, reliable, 
high-throughput and less expensive in vitro tumor 
model would be useful for characterizing and 
screening antibodies and immunoconjugates for can-
cer therapy. 
Here, we describe a detailed protocol to establish 
an in vitro 3D tumor spheroid model. This model can 
be used to identify potential new therapeutic targets 
that are highly expressed in mesothelioma cells in 3D 
spheroids, but not in monolayers, and therefore be 
relevant in the 3D tumor. Furthermore, this protocol 
may be easily applied to in vitro studies of other tu-
mor-targeting antibodies and immunoconjugates in 
vitro. It may also be a useful system for screening tu-
mor penetrating monoclonal antibodies by antibody 
engineering technologies such as phage display 7. 
Development of the protocol 
Most studies of anticancer drugs consider only 
cellular and/or genetic mechanisms at the level of the 
single cell. However, drug penetration is a highly 
important additional mechanism and requires a more 
complex cellular environment to study. Indeed, in 
vitro spheroid models have become the most com-
monly used tools to assess drug penetration.         
Although animal studies, when feasible, hold the ad-
vantage of mimicking the clinical environment most 
closely, in vitro spheroids offer the benefit of being 
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able to examine the distribution of drugs in the ab-
sence of complicating factors such as pharmacokinet-
ics, which often differ between mice and humans. Not 
only are tumor spheroids an excellent model to eval-
uate drug penetration, they play an increasingly 
meaningful role in drug discovery and development.  
In 2006, Ivascu and Kubbies at Roche Pharma-
ceutical Research Oncology in Germany first reported 
a simple method to generate tumor spheroids for po-
tential high-throughput functionality and toxicity 
analysis.4 Briefly, a defined number of cancer cells 
ranging from 1,000 to 20,000 were seeded into wells of 
poly(2-hydroxyethylmethacrylate)–coated, 96-well, 
round- or conical-bottom plates in standard growth 
medium and centrifuged for 10 minutes at 1000 x g. 
Within 24 hours of culturing, this procedure gener-
ated individual spheroids in each well with homoge-
neous sizes, morphologies, and stratification of pro-
liferating cells found in the rim that also include dying 
cells in the core region.4 In addition, by adding base-
ment membrane extract Matrigel to some cell lines, 
they were able to improve the structure from an ag-
gregate to spheroid morphology. In 2008, after evalu-
ating several techniques, V. Courtney Broaddus’ 
group at the University of California San Francisco 
(USA) first established mesothelioma spheroids for 
the study of apoptotic resistance using multicellular 
spheroids1, modifying the method originally reported 
by Ivascu and Kubbies.1 Interestingly, although 
Broaddus’ study did not use any basement membrane 
extract, they found the formation of spheroids to be 
stably intact.  
 Our laboratory at the National Cancer Institute 
(NCI) focuses on producing human monoclonal an-
tibodies (mAbs) for the development of cancer ther-
apy. Although leukemia treatments involving mAbs 
have been in clinical use for years, this approach has 
not been as successful for solid tumors. The prolifera-
tion of tumor cells forces blood vessels apart, reducing 
vascular density and creating a population of cells 
distant (>100μm) from vessels.5 Drugs generally do 
not penetrate further than three to five cell diameters 
from blood vessels, thereby depriving more distantly 
located tumor cells of any drugs. Penetrating antibody 
technology is increasingly seen by many to be the holy 
grail of antibody therapy. A limitation in our ability to 
identify and evaluate effective penetrating antibody 
reagents has been the lack of an in vitro model that 
recapitulates the features of a solid tumor. In the last 
two years, in collaboration with our group, the Taka-
yama laboratory at the University of Michigan has 
produced two publications related to 3D spheroid 
cultures 10, 11. One study established co-cultures by 
introducing different types of cells on the membrane 
or in the bottom chamber of commercially available 
Transwells. They found that cancer cells formed 3D 
spheroids while maintaining their viability and used 
this procedure to evaluate mouse embryonic stem 
(mES) cell differentiation based on heterogeneous 
cell-cell interactions11. Co-culture of mES cells and 
HepG2 human hepatocellular cancinoma (HCC) cells 
decreased SOX17 expression of mES cells, and direct 
cell-cell contact further decreased SOX17 expression, 
indicating that co-culture with HepG2 cells inhibits 
endoderm differentiation. Another study described 
high-throughput 3D spheroid culture and drug test-
ing using a 384-well format hanging drop culture 
plate10.  
In collaboration with V. Courtney Broaddus, we 
made a 3D spheroid model culture using a human 
mesothelioma cell line and primary cell lines isolated 
from the ascites of malignant mesothelioma patients. 
Using this model, we treated spheroids with SS1P, a 
recombinant immunotoxin targeting mesothelin6, and 
evaluated how the microenvironment affected the 
ability of the drug to penetrate a 3D cancer cell mass 
and kill cancer cells.8 Mesothelin is highly expressed 
in mesothelioma and several other human cancers, 
including pancreatic adenocarcinomas, ovarian can-
cers, lung adenocarcinomas and cholangiocarcino-
ma.2, 3, 9 Although mesothelioma cells grown as mon-
olayers or as spheroids express comparable levels of 
mesothelin, we observed that spheroids were at least 
100 times less sensitive to SS1P and that penetration 
within spheroids was limited after four hours. The 
core area of spheroids revealed a substantial number 
of tight junctions, along with a significant increase in 
expression of E-cadherin, a protein involved in the 
assembly and sealing of tight junctions and highly 
expressed in malignant mesothelioma. Moreover, 
siRNA silencing and antibody inhibition targeting 
E-cadherin enhanced SS1P immunotoxin therapy in 
vitro.8  
Advantages and limitations of the present 
protocol 
3D spheroid culture is often complicated to fol-
low and varies frequently according to individual 
practices. It can be cumbersome for labs with limited 
resources and expensive to manage. However, it is 
worthwhile to mention that although not all features 
of solid cancers, such as the influence of stroma and 
immune cells, are modeled by multicellular sphe-
roids, spheroids do reflect many important properties 
of solid tumors, including the development of an ex-
tracellular matrix, tight junctions between epithelial 
cells, and gradients of nutrient concentration and cell 
proliferation from the exterior to the center. Spheroids 
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can develop central necrosis and regions of hypoxia. 
By incubating spheroids with an anticancer drug, it 
then becomes possible to examine the kinetics of drug 
penetration. Unlike a previous method12, the protocol 
described here is relatively simple and straightfor-
ward to learn, rapid in producing samples, and eco-
nomically feasible. 
Experimental Design 
NCI-H226 (American Type Culture Collection or 
ATCC, Rockville, MD) is a human lung squamous 
carcinoma cell line. HepG2 and Hep3B (ATCC) are 
two human liver cancer (HCC) cell lines. NCI-M-03 
and NCI-M-13 (Raffit Hassan, NCI, Bethesda, MD) are 
two human mesothelioma primary cell lines isolated 
from the ascites of malignant mesothelioma patients 
treated at the NCI.8 
 
MATERIALS  
REAGENTS FOR FORMATION OF 
SPHEROIDS 
 Poly-HEMA (Sigma; Cat. #P3932) 
 95% ethanol (in milliQ water) 
 U-bottomed 96-well plates (Greiner; Cat. 
#650185) 
 SS1P (Ira Pastan, Laboratory of Molecular Biol-
ogy, NCI, Bethesda, MD)  
 RPMI 1640 Media (Invitrogen; Cat. #21870-076) 
containing 10% fetal bovine serum (FBS), 1% 
L-glutamine (Invitrogen, Carlsbad, CA) and 1% 
penicillin-streptomycin (Invitrogen, Carlsbad, 
CA) 
 FreeStyle 293 Media (Invitrogen; Cat. 
#12338-018) 
 Accutase (BD Biosciences; Cat. #561527) 
 T-75cm2 tissue culture flasks (Sarstedt; Cat. 
#83.1813.002) 
ADDITIONAL REAGENTS FOR 
CHARCTERIZATION OF SPHEROIDS 
 Coomassie Plus Protein Assay Reagent (Thermo 
Scientific; Cat. #1856210) 
 RNeasy Mini Kit (Qiagen; Cat. #74104)  
 Cell Counting Kit-8 (Dojindo Laboratories; Cat. 
#CK04) 
 Costar white opaque-walled 96-well plates ade-
quate for cell culture (Corning; Cat. #3922) 
 CellTiter-Glo Luminescent Cell Viability Assay 
(Promega; Cat. #G7572) 
REAGENT SETUP 
Lysis buffer  
To make a stock solution of lysis buffer, combine 
one “Complete Mini-EDTA free” protease inhibitor 
tablet (Roche; Cat. #1873580), 10 mL of RIPA buffer, 
and 1 mL of 20% SDS. 
Poly-HEMA  
Prepare a 120 mg/mL stock solution of 
poly-HEMA in 95% ethanol. Incubate while stirring 
with a sterile magnetic bar at room temperature 
(15–20°C) overnight. To make a working solution of 
Poly-HEMA, pipette 1 mL of Poly-HEMA stock solu-
tion into 23 mL of 95% ethanol to obtain a final con-
centration of 5 mg/mL (this volume is enough to coat 
four plates). Vortex solution and leave at room tem-
perature (15–20°C) until ready to coat. Prepare fresh 
working solution every time new plates are made. 
EQUIPMENT 
Device (plate shaker) for mixing multiwell plates 
Luminometer or charge-coupled device (CCD) 
camera imaging device capable of reading multiwell 
plates 
PROCEDURE  
Preparation of non-adsorbent poly-HEMA 
plates  
1 Pipette 60 μL of poly-HEMA stock solution 
into each well of a 96-well U-bottomed plate. 
SEE TROUBLESHOOTING (1) 
2 Evaporate with lids on at room tempera-
ture (15–20°C) inside a sterile hood for 72 hours. 
SEE TROUBLESHOOTING (2) 
3 After plates are completely dried, seal with 
parafilm, and store at 4ºC.  
4 Before use, bring to room temperature 
(15-20ºC) and sterilize in the hood with lids off for 30 
minutes.  
Preparation of Spheroids 
5 Maintain cell line as adherent monolayer 
cultures in RPMI 1640 medium supplemented with 
10% FBS, L-glutamine, and penicillin-streptomycin. 
6 Incubate at 5% CO2 with balance of air at 
37°C.  
7 Seed at 2x105cells/mL in T-75cm2 tissue 
culture flasks. 
8 Change cell media twice a week.  
9 Rinse the cells with PBS and add 5 mL of 
Accutase to detach cells and incubate at 37°C for 3-5 
minutes. 
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10 Neutralize with 5 mL of growth media and 
perform a cell count. 
11 Centrifuge at 216 x g at room temperature 
(15–20°C) for 5 minutes. 
12 Dilute cell concentration to 5x104 cells/mL 
with growth media in order to form 10,000-cells per 
well spheroids (approximately 1 million cells are 
needed per plate). 
13 Pipette 200 µL of the cell suspension into 
each well of the 96-well plate pre-coated with 
poly-HEMA. 
14 Centrifuge the plate at 216 x g at room 
temperature (15–20°C) for 10 minutes. 
15 Incubate for 24-48 hours at 37°C, 5% CO2. 
SEE TROUBLESHOOTING (3) 
Preparation of Cell Lysate from Spheroids and 
Monolayers 
Spheroids 
16 Pipette growth media and spheroid com-
pletely from each well and collect in a 50 mL tube. 
17 Centrifuge at 216 x g at room temperature 
(15–20°C) for 5 minutes, aspirate the supernatant, and 
resuspend the cells with 1.5 mL of PBS. 
18 Centrifuge at 216 x g at room temperature 
(15–20°C) for 5 minutes, aspirate the supernatant, and 
resuspend the cells in 50 µL of lysis buffer (for ap-
proximately 1 million cells). 
19 Vortex thoroughly. 
20 Repeat four cycles of freezing at 80ºC for 
approximately 10 minutes and thawing at 37ºC for 
approximately 20 minutes. 
21 Centrifuge at 216 x g at room temperature 
(15–20°C) for 1 minute, and collect all of the superna-
tant. 
22 Measure concentration by Coomassie stain, 
a reliable standard for protein quantification. Load 
approximately 50-100 µg of cell protein lysate per lane 
for western blot analysis. 
Monolayers 
23 Aspirate growth media of monolayer cells 
and rinse three times with PBS. 
Δ CRITICAL STEP Allow monolayer cells to 
grow for two to three days after seeding until 50-60% 
confluent. 
24 Add 2 mL of PBS and scrape monolayer 
cells on ice, and collect in a 15 mL tube.  
25 Add another 2 mL of PBS to the plate, 
scrape, and collect the remaining cells. 
26 Centrifuge at 216 x g at room temperature 
(15–20°C) for 5 minutes, aspirate the supernatant, and 
resuspend the cells in 50 µL of lysis buffer (for ap-
proximately 1 million cells) 
27 Vortex thoroughly.  
28 Repeat four cycles of freezing and thawing 
(-80º/37ºC). 
29 Centrifuge at 216 x g at room temperature 
(15–20°C) for 5 minutes, and collect all supernatant. 
30 Measure concentration by Coomassie stain. 
Load approximately 50-100 µg of cell protein lysate 
per lane for western blot analysis. 
SEE TROUBLESHOOTING (4) 
Purification of RNA for Microarray Analysis 
31 Collect monolayer and spheroid cell lysate 
on three separate days. 
Δ CRITICAL STEP Save a sufficient amount of 
cell lysate for RNA quality validation. 
32 Follow manufacturer’s kit instructions to 
purify RNA. 
SEE TROUBLESHOOTING (5) 
WST Assay 
33 Form 3D spheroids on a 96-well 
poly-HEMA-coated plate. 
34 Allow monolayers and spheroids to grow 
for 24 hours. 
35 Add 20 µL of SS1P/BL22 (negative con-
trol)/Cycloheximide (CMH) (positive control) to 200 
µL of RPMI growth media per well for a 1:10 dilution. 
SEE TROUBLESHOOTING (6) 
36 Allow monolayers and spheroids to incu-
bate for 72 hours with immunotoxin. 
37 Prepare a sufficient volume of WST rea-
gent in serum-free FreeStyle media (e.g. 1 mL of rea-
gent in 9 mL of media). 
38 Remove growth media and replace with 
100 µL/well of a working solution of WST reagent- 
FreeStyle media mentioned in the previous step. 
39 Transfer all 100 µL containing each sphe-
roid from each well to a flat-bottom 96-well plate. 
40 Allow to incubate for 2-4 hours at 37ºC un-
til brown-yellow color develops. 
41 Measure absorbance at 450 nm with refer-
ence wavelength of 650 nm. 
ATP Assay 
42 Form 3D spheroids on a 96-well 
poly-HEMA coated plate. 
43 Allow monolayers and spheroids to grow 
for 24 hours. 
44 Seed 10,000 cells/well for monolayer cells 
and one 10,000-cell spheroid/well containing 200 µL 
of RPMI growth media in a 96-well flat bottom plate. 
45 Add 20 µL of SS1P and BL22 (negative 
control) from 1000 ng/mL to 0.0001 ng/mL to each 
well. 
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SEE TROUBLESHOOTING (7) 
46 Incubate for 72 hours at 37ºC. 
47 Transfer monolayer cells and spheroids via 
a pipette to opaque-walled multiwell plates in culture 
medium (100 µL/well for 96-well plates). 
48 Prepare control wells containing medium 
without cells to obtain background luminescence 
value. 
49 Equilibrate the plate and its contents at 
room temperature (15-20ºC) for approximately 30 
minutes. 
50  Add a volume of CellTiter-Glo Reagent 
equal to the volume of cell culture medium present in 
each well (e.g., add 100 µL of reagent to 100 µL of 
growth media containing cells for a 96-well plate). 
51 Mix contents for 2 minutes on an orbital 
shaker to induce cell lysis. 
52 Allow plate to incubate at room tempera-
ture (15-20ºC) for 10 minutes to stabilize luminescent 
signal. 
53 Measure luminescence. 
SEE TROUBLESHOOTING (8) 
TROUBLESHOOTING 
1. For proper storage, the stock solution of 
poly-HEMA can be stored at room temperature 
(15-20ºC) indefinitely. 
2. It is optional to evaporate with the lids on 
at room temperature (15–20°C) on the bench for 1 to 2 
weeks for slower drying, or to evaporate at 37°C in-
side a humidity-free bacterial incubator for 48 hours.  
3. Within six hours, mesothelioma cells begin 
to form as an aggregate and should be left alone as 
they may be easily disturbed by pipetting. By 24 
hours, most mesothelioma cells form into a disk-like 
shape called a multicellular spheroid and can be 
transferred gently by a pipette without dissociating. 
4. For proteins that may be more difficult to 
visualize or detect (e.g. E-Cadherin), use at least 100 
µg of cell protein lysate per lane for western blot 
analysis. 
5. Selected GeneChip Human Genome U133 
Plus 2.0 Array was performed by NCI Affymetrix 
Group (Frederick, MD) for reliability. For optimal 
results, the recommended final concentration of RNA 
for array analysis is 100 ng/mL in a 6 µL volume per 
sample. 
6. To properly prepare SS1P at the original 
concentration (0.25 mg/mL): For 100 ng/mL final 
concentration, add 20 µL of 1 µg/mL SS1P into 100 µL 
growth media per well. For 1000 ng/mL final con-
centration, add 20µl of 10µg/ml SS1P into 200µl 
growth media per well. Original concentration of 
BL22 (1 µg/mL): For 100 ng/mL final concentration, 
add 20 µL of 1 µg/mL BL22 into 200 µL growth media 
per well. Original concentration of CHM (100 
µg/mL): For working solution, dilute 1 µL in 99 µL of 
growth media. For 1:1000 final concentration, add 20 
µL of CHM working solution into 200 µL growth me-
dia per well. 
7. To properly prepare SS1P at the original 
concentration (0.25 mg/mL): Dilute to 10,000 ng/mL 
working solution (adding 20 µL of this in 200 µL of 
cell suspension results in a final concentration of 1000 
ng/mL). For a 1000 ng/mL working solution, add 100 
µL of 10,000 ng/mL SS1P in 900 µL of growth media 
(adding 20 µL of this in 200 µL of cell suspension re-
sults in a final concentration of 100 ng/mL). Continue 
to serially dilute 100 µL of SS1P in 900 µL of growth 
media. Original concentration of BL22 (684 µg/mL): 
Dilute to 10,000 ng/mL working solution (adding 20 
µL of this in 200 µL of cell suspension results in a final 
concentration of 1000 ng/mL). For a 1000 ng/mL 
working solution, add 100 µL of 10,000 ng/mL BL22 
in 900 µL of growth media (adding 20 µL of this in 200 
µL of cell suspension results in a final concentration of 
100 ng/mL). Continue to serially dilute 100 µL of 
BL22 in 900 µL of growth media. 
 8. It is highly recommended to do more than 
one type of cell proliferation or viability assay (e.g. 
WST and ATP). 
TIMING 
Step 1-4, Preparation of non-adsorbent 
Poly-HEMA plates: 3 days 
Step 5-15, Preparation of Spheroids: 2 days 
Step 16-30,  Preparation of Cell Lysate: 3 hours 
Step 31-32, Purification of RNA for Microarray 
Analysis: 1 day 
Step 33-41, WST Assay for SS1P-Treated Mono-
layers and Spheroids: 4 days 
Step 42-53, ATP Assay for SS1P-Treated Mono-
layers and Spheroids: 4 days 
ANTICIPATED RESULTS 
Using the experimental conditions described in 
this protocol, almost all of the established cancer cell 
lines and primary cells isolated from patients are able 
to form 3D spheroids in vitro (Fig. 2). We found that 
the mesothelioma and HCC cells we used formed 
spheroids well.   
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Figure 2. Establishment of in vitro tumor spheroids. Microscopic images of monolayers and spheroids of human 
cancer cell lines, NCI-H226 (mesothelioma), HepG2 (hepatocellular carcinoma or HCC), Hep3B (HCC), and primary 
mesothelioma lines, NCI-M-03 and NCI-M-13, isolated from patients taken after 24 hours. Scale bars, 400 µm. 
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Within only 2 days after seeding cells, spheroids 
are ready for tumor penetration studies of antibodies 
or immunoconjugates, RNA extraction for microarray 
analysis, protein lysis for proteomics analysis or dis-
covery of tumor penetration antibodies by phage dis-
play and other antibody technologies. 
To investigate how tumor microenvironments 
affect the killing activity and penetration of an anti-
body agent, monolayers and spheroids were treated 
with SS1P and a negative control. Cell growth inhibi-
tion (WST) and cell viability (ATP) assays showed 
that the IC50 of SS1P for spheroids was >1000 ng/mL, 
at least 100 times the IC50 for monolayers, ~10 ng/mL, 
after 72 hours. Both assays revealed that greater than 
50% of the cancer cells from spheroids could not be 
killed by SS1P concentrations as high as 1,000 ng/mL. 
Finally, we tested SS1P on primary lines isolated from 
malignant mesothelioma patients and confirmed that 
SS1P was far less effective on spheroids. 
We explored two different experimental ap-
proaches to examine the roles of protein regulation in 
regard to immunotoxin penetration. The first in-
volved silencing E-Cadherin using siRNA. A reduc-
tion in protein expression (greater than 80%) was ob-
served followed by an increased sensitization to SS1P 
therapy. Finally, an inhibitory antibody against 
E-Cadherin also demonstrated enhanced anti-tumor 
activity only if added before, but not after, spheroid 
formation. 
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